Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Recurrence × etoposide phosphate × Clear all

Phase

Status

Terminated 2 Withdrawn 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 2 Small Cell Lung Carcinoma 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Metastatic NUT Carcinoma 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Myeloid, Acute 1

Interventions

Dexamethasone 8 venetoclax 4 Rituximab 4 selinexor 3 pembrolizumab 3 ibrutinib 3 Lenalidomide 3 Gemcitabine 3 Drug Therapy 3 Cytarabine 3 Bendamustine Hydrochloride 3 gilteritinib 2 fludarabine phosphate 2 carfilzomib 2 Tablets 2 Surveys and Questionnaires 2 Oxaliplatin 2 Cetuximab 2 Calcium Dobesilate 2 Busulfan 2 Bortezomib 2 Azacitidine 2 vistusertib 1 urelumab 1 tucotuzumab celmoleukin 1 trametinib 1 tocilizumab 1 tisagenlecleucel 1 thymoglobulin 1 temsirolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00776802 2013-06-25

GCS-100LE

La Jolla Pharmaceutical Company

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡